Current therapies for endometriosis, which focus on reducing systemic oestrogen levels, are limited by side effects and poor efficacy. Zhao et al. previously developed two oestrogen receptor (ER) ligands with strong anti-inflammatory activity — chloroindazole (CLI) and oxabicycloheptene sulfonate (OBHS), which target ERα and ERβ, respectively. Here, they show that together, OBHS and CLI prevent the establishment of endometriotic lesions and reverse the growth and progression of established lesions in a mouse model of endometriosis, without affecting reproductive physiology and fertility.
References
Zhao, Y. et al. Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis. Sci. Transl Med. 7, 271ra9 (2015)
Rights and permissions
About this article
Cite this article
Crunkhorn, S. Suppressing the oestrogen-inflammatory axis. Nat Rev Drug Discov 14, 166 (2015). https://doi.org/10.1038/nrd4576
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4576